Breast cancer management in 2021: A primer for the obstetrics and gynecology
- PMID: 35307285
- DOI: 10.1016/j.bpobgyn.2022.02.004
Breast cancer management in 2021: A primer for the obstetrics and gynecology
Abstract
Breast cancer is the most commonly diagnosed cancer and is the leading cause of cancer death in women worldwide. Several factors increase the risk of breast cancer development, including patient characteristics, lifestyle habits, and predisposing genetic mutations. Once a diagnosis of breast cancer has been established, treatment decisions are guided by breast cancer stage and phenotype. Immunohistochemistry is used to quantify estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) expressions. In this chapter, we will focus on the management of localized and metastatic breast cancer, guided by the breast cancer hormone receptor status (ER and PR expression) and HER2 expression identified at diagnosis.
Keywords: Breast cancer; Chemotherapy; Endocrine therapy; Estrogen receptor; Human epidermal growth factor 2.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors have no conflicts of interest.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous